ePrivacy and GPDR Cookie Consent by Cookie Consent
Oncodna logo - wide
Home
Healthcare Providers
Biopharma
Patients & Relatives
About us ▾
Our StoryAwardsTeamCareers
Activity ▾
NewsMDIP (new)Congresses & EventsWebinars
Library ▾
BrochuresPodcast (new)Scientific publications and postersVideos
Contact
OncoDNA for 
Home Healthcare Providers Biopharma Patients & Relatives

Our solutions are reimbursed

There may be different options for financing your biomarker tests

Scroll down to discover

A growing list of countries

Our tests are reimbursed in a growing number of countries. The reimbursement depends on your public or private health insurance scheme, and either some or all our tests may be covered. Our biomarker tests may also be available through certain research projects in which your oncologist may be taking part.

The Liberal Mutuality Namur-Hainaut
The Liberal Mutuality Namur Hainaut is financing 50% of OncoDEEP and partially OncoSTRA&GO. Discover in video how to proceed

La Cagnotte de Proches
OncoDNA signed a partnership with “La Cagnotte des Proches” in order to help patients in Belgium and France finance their biomarker tests. La Cagnotte Des Proches is an online crowdfunding site with the moto "Patients must no longer suffer the financial consequences of an illness, especially when their survival or well-being is at stake".

MDLUX2, a molecular diagnostics program from the INC 
OncoDNA was selected as the provider of molecular diagnostic services for the program MDLUX2 from the INC (Institut National du Cancer), funded by IBBL (Integrated BioBank of Luxembourg), the Fondation Cancer and the Fondatioun Kriibskrank Kanner. Hundreds of patients are expected to benefit from the program.

Lonpac Insurance Bhd
Secure Cancer Care is a specific medical services insurance policy (from Lonpac Insurance Bhd) that pays for the laboratory preparation of tissue samples for biomarker testing, treatment recommendation and subsequent follow-up monitoring. All those services are offered by OncoDNA, their preferred provider.